Deciding to administer CAR T-cell therapies is an institutional commitment that requires educating all clinicians who will be involved and partnerships with other organizations, said Stephen Schuster, MD, of the Perelman School of Medicine.
Deciding to administer CAR T-cell therapies is an institutional commitment that requires educating all clinicians who will be involved and partnerships with other organizations, said Stephen Schuster, MD, of the Perelman School of Medicine.
Transcript
What education efforts are needed for patients and clinicians when new treatments like CAR T therapies first emerge?
It’s an institutional commitment if one is going to do CAR T-cell therapy; it’s not just a single physician or physician’s office. It involves multiple people, there’s a chain of people that are involved from the blood bank or transfusion service that receives the cells and thaws the cells and administers the cells to the physicians and nurse practitioners and nurses that are caring for the patients during infusion and after infusion of the cells.
And those people need to be educated not only in the specific adverse events of special interest—cytokine release, neurotoxicity—but also in terms of handling the cells and making sure that the patient is in the proper environment for surveillance for subsequent syndromes, either as an outpatient or an inpatient, depending on the product used. Most leukemia patients, kids, will be admitted to the hospital.
So, what’s helpful is the sponsors of the 2 products that have a commercial label, that’s tisagenlecleucel or Kymriah, and the other one is axicabtagene ciloleucel, which is called Yescarta, they have REMS [Risk Evaluation and Mitigation Strategy] programs. So, these are programs that will educate people at all points in the chain on what to expect, what the roles are, what the proper responses are and actually have a test and things like that. And that’s the first step in getting educated.
Obviously, experience is important and the only way you can get that is by doing it. I think that people who are new to it, in addition to the REMS programs, should probably have a relationship with someone who is experienced, so if they run into problems they have somebody they can call and bounce problems off of.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More